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Abstract
Objective. Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine
oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the
study was to investigate the long-term safety of LESU + XOI therapy.
Methods. Safety data were pooled from three 12-month phase III (core) trials evaluating LESU 200 and 400 mg/day
combined with an XOI (LESU200+XOI and LESU400+XOI), and two 12-month extension studies using descriptive stat-
istics. To adjust for treatment duration, treatment-emergent adverse events (TEAEs) were expressed as exposure-ad-
justed incidence rates (patients with events per 100 person-years).
Results. In the core studies, exposure-adjusted incidence rates for total and total renal-related TEAEs were comparable
for XOI alone and LESU200+XOI but higher with LESU400+XOI. Exposure-adjusted incidence rates for serum creatinine
(sCr) elevations 51.5baseline were 2.9, 7.3 and 18.7, respectively. Resolution (sCr 41.2baseline) occurred in
7590% of all events, with 6675% occurring without any study medication interruption. Major adverse cardiovascular
events were 3, 4 and 9 with XOI, LESU200+XOI and LESU400+XOI, respectively. Longer exposure in core+extension
studies did not increase rates for any safety signals.
Conclusion. At the approved dose of 200 mg once-daily combined with an XOI, LESU did not increase renal, cardio-
vascular or other adverse events compared with XOI alone, except for sCr elevations. With extended exposure in the
core+extension studies, the safety profile was consistent with that observed in the core studies, and no new safety
concerns were identified.
Key words: gout, lesinurad, serum creatinine, treatment-emergent adverse events, xanthine oxidase inhibitor,
combination therapy, renal adverse events, cardiovascular adverse events
Rheumatology key messages
. Gout patients had comparable renal-related treatment-emergent adverse events with xanthine oxidase inhibitors
± lesinurad 200 mg after 12 months.
. In gout patients, adding lesinurad to xanthine oxidase inhibitor monotherapy increased serum creatinine eleva-
tions vs monotherapy alone.
. Treating gout patients with lesinurad 200 mg + xanthine oxidase inhibitors for 24 months revealed no new safety
concerns.
Introduction
Gouty arthritis is a significant public health problem, driven
by excess body stores of uric acid, reflected in sustained
hyperuricaemia [1, 2]. If hyperuricaemia in patients with
gout is not adequately treated, deposition of monosodium
urate crystals commonly progresses in joints and periarticu-
lar tissues, and promotes increased symptoms and joint
damage [1, 2]. Long-term therapy for gout, advocated
by multiple Rheumatology Society guidelines, includes
pharmacologic measures to reduce serum urate (sUA)
levels to <6.0 mg/dl and even lower (<5.0 mg/dl) for
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severe disease [3, 4]. Success of this therapeutic approach,
as demonstrated in both early and advanced stages of
gout, promotes dissolution of deposited urate crystals and
eventual reduction of acute gouty arthritis flares and syno-
vitis [5, 6]. The recommended first-line urate-lowering ther-
apy (ULT) approach in treatment of gout is use of a xanthine
oxidase inhibitor (XOI), either allopurinol or febuxostat [3, 4].
The XOIs inhibit urate production [3, 4]; however, many pa-
tients with gout fail to achieve their serum urate target using
only XOI monotherapy [79], often due to poor compliance
or failure to up-titrate the dose. In those circumstances,
treatment recommendations include use of a uricosuric
alone (probenecid or benzbromarone) or combination
ULT, using XOI and uricosuric agents to provide comple-
mentary mechanisms of action [3, 4]. As the amount of uric
acid renally excreted is decreased by XOI therapy, combin-
ation XOI and uricosuric therapy can more effectively lower
body uric acid stores than an XOI alone, by increasing the
major pathway of uric acid excretion by the kidney [3, 4].
Lesinurad (LESU) is a selective uric acid reabsorption
inhibitor approved in the United States and Europe at a
200 mg daily dose in combination with an XOI for the treat-
ment of hyperuricaemia associated with gout in patients
not achieving target sUA levels on an XOI alone [10]. LESU
reduces sUA by inhibiting uric acid transporter 1 (URAT1),
which is responsible for the majority of the reabsorption of
filtered urate from the renal tubular lumen [11]. LESU in-
creases the excretion of uric acid by the kidney and
lowers sUA levels [12, 13].
The LESU clinical programme included three pivotal pla-
cebo-controlled, 12-month phase III (core) studies (CLEAR 1,
CLEAR 2 and CRYSTAL) that evaluated LESU 200 mg
(LESU200) and LESU 400 mg (LESU400), combined with
an XOI [1416]. In these trials, greater proportions of patients
treated with LESU200 or LESU400 combined with an XOI
achieved sUA targets at 6 and 12 months vs an XOI alone.
However, concerns were raised about the safety of combin-
ing an XOI with LESU 400 mg. LESU 400 mg monotherapy
significantly lowered sUA compared with placebo for up to
18 months [13]. However, there was a high incidence of
serum creatinine (sCr) elevations and renal-related adverse
events, including serious adverse events. Therefore, it was
important to obtain data with the combination therapy over
longer periods. Patients completing the core studies were
eligible to enter extension studies, in which patients treated
with LESU at 200 mg and 400 mg doses in combination with
an XOI for up to 2 years, exhibited continued improvements
in signs and symptoms of gout, including reductions in
tophi and gout flares, while maintaining lower sUA levels
[1719]. We investigated the safety of LESU200+XOI and
LESU400+XOI in the three core studies and the two exten-
sion studies for a total treatment period of up to 2 years.
Methods
Patient population
Patients with a diagnosis of gout who entered the core
studies were aged 1885 years [11]. The inclusion criteria
for CLEAR 1 and CLEAR 2 were sUA levels 56.5 mg/dl
while on allopurinol and 52 gout flares in the previous
12 months. The inclusion criteria for CRYSTAL were sUA
levels 56.0 mg/dl for patients taking ULT or 58.0 mg/dl
for patients not taking ULT, and 51 measurable tophi on
hands/wrists and/or feet/ankles. Patients with creatinine
clearance <30 ml/min calculated by Cockcroft-Gault for-
mula were excluded from all three studies.
Study design
The three core studies evaluated LESU200 and LESU400
combined with an XOI, either allopurinol (CLEAR 1 and 2;
NCT01510158, NCT01493531) or febuxostat (CRYSTAL,
NCT01510769) [1416]. The primary efficacy end point in
CLEAR1 and CLEAR2 was the proportion of patients with
sUA <6.0 mg/dl by month 6 in each treatment group. In
the CRYSTAL study, patients with tophaceous gout
were treated with febuxostat for 3 weeks before being
randomized to febuxostat alone, LESU200+XOI or
LESU400+XOI, and the primary end point was the propor-
tion of patients with sUA <5.0 mg/dl by month 6 in each
treatment group. In the CLEAR (NCT01808131) and
CRYSTAL (NCT01808144) extension studies, LESU-trea-
ted patients who completed the core studies continued to
receive LESU+XOI at the same dose (200CONT or
400CONT). Patients initially treated with only an XOI in
the core studies were randomized 1:1 to receive
LESU200 or LESU400 in addition to the XOI provided in
the core trial (Supplementary Fig. S1, available at
Rheumatology online). Safety was assessed throughout
both the core and extension studies.
Safety assessments
Safety assessments included treatment-emergent ad-
verse events (TEAEs); major adverse cardiovascular
events (MACE): cardiovascular (CV) death, myocardial in-
farction or stroke [20]; CV and vascular TEAEs; and renal-
related and kidney stone TEAEs. All TEAEs were reported
by investigators and captured in the study case report
forms. Investigators were instructed to provide a clinical
diagnosis whenever possible. The diagnosis was deter-
mined solely by the investigator, not predefined by the
sponsor. Laboratory abnormalities (e.g. serum creatinine
1.5baseline) were considered a TEAE only if reported so
by the investigator, therefore not all abnormalities were
TEAEs. Any clinical diagnosis associated (e.g. renal im-
pairment, renal failure) was provided by the investigator.
Severity was determined by the investigator according to
the Rheumatology Common Terminology Criteria for
Adverse Events, as was the relationship to study drug. A
predefined list of 36 diagnoses to capture all renal-related
adverse events (AEs) and 11 diagnoses to capture all
kidney stone-related AEs [Medical Dictionary for
Regulatory Activities (MedDRA) version 14.0 preferred
terms; see Supplementary Table S1, available at
Rheumatology online] was used during safety analysis,
utilizing the diagnoses provided by the investigators. For
example, if an investigator reported a serum creatinine
elevation as a TEAE, the MedDRA term used would be
blood creatinine increase. Serious AEs were defined as
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AEs that resulted in death, hospitalization or prolongation
of existing hospitalization; or persistent or significant dis-
ability or congenital anomaly; were life threatening; or
were considered an important medical event. An adjudi-
cation committee, blinded to treatment assignment, pro-
spectively reviewed all deaths and serious CV events.
Institutional review boards (IRBs)/ethics committees
(ECs) from each country reviewed and approved the
protocol for each study. The central IRBs/ECs were
Schulman Associates Institutional Review Board, Inc.,
Cincinnati, OH, US; Comite´ d’E´thique Hospitalo-
Facultaire  Hoˆpital Erasme, Brussels, Belgium; Health
and Disability Ethics Committees, Wellington, New
Zealand; and Komisja Bioetyczna przy Okregowej Izbie
Lekarskiej w Gdan´sku, Gdan´sk, Poland. The studies
were conducted in accordance with Independent Ethics
Committee E6 Good Clinical Practice, the Declaration of
Helsinki (October 2008), and applicable local regulatory
requirements. Patients provided written informed consent;
they were permitted to withdraw from the medication or
the study at any time.
Statistical analysis
Data were pooled for each treatment group from the three
core studies and two extension studies. To adjust for
varying durations of treatment, TEAEs were expressed
as exposure-adjusted incidence rates (EAIRs), defined
as the number of patients with events per 100 person-
years (PY). No statistical analyses were performed, other
than for MACE where the Poisson exact method was used
to calculate the 95% CI.
Results
Patients
A total of 1332 patients were exposed to LESU during the
core and extension study periods: LESU200+XOI (n= 666)
and LESU400+XOI (n= 666). The patients were predomin-
ately male (95%) with an average age at baseline of the
core studies of 52 years and body mass index of 34 kg/m2.
The mean duration of gout was 12 years with an average
experience of six gout flares in the previous 12 months
(Table 1). At screening, one third of the patients had
tophi, two thirds had hypertension, almost half had hyper-
lipidaemia and 17% had diabetes mellitus. 40% of pa-
tients had an estimated creatinine clearance (eCrCl)
>90 ml/min, 41% had eCrCl 60<90 ml/min and 19%
had eCrCl 30<60 ml/min. The average sUA at baseline
was 6.5 mg/dl.
TEAE rates
The EAIRs of TEAEs in the core studies and the core +
extension studies are presented in Table 2. In the core
studies, EAIRs were similar with LESU200+XOI and XOI
alone and were generally higher with LESU400+XOI for
any TEAE, any TEAE with Rheumatology Common
Toxicity Criteria grade 3 or 4, those possibly related to
randomized study medication, possibly related to XOI,
possibly related to prophylaxis, serious TEAEs, fatal
TEAEs, and those leading to discontinuation of LESU.
The number of these TEAEs increased with longer expos-
ure to LESU200+XOI or LESU400+XOI in the core + ex-
tension studies, but EAIRs were lower than in the core
studies.
TABLE 1 Demographic and clinical characteristics at screening/baseline in pooled core phase III studies
XOI alone
(n= 516)
LESU 200 mg
+XOI (n= 511)
LESU 400 mg
+XOI (n= 510)
Male, n (%) 492 (95.3) 489 (95.7) 482 (94.5)
Age, mean (S.D.), years 52.2 (11.1) 51.9 (11.0) 52.1 (11.3)
Weight, mean (S.D.), kg 105.5 (22.3) 108.0 (22.4) 106.2 (23.7)
Body mass index, mean (S.D.), kg/m2 33.7 (6.2) 34.3 (6.2) 33.8 (6.9)
Duration since gout diagnosis, mean (S.D.), years 12.2 (9.6) 13.2 (10.2) 11.5 (9.3)
Tophi at screening, n (%) 183 (35.5) 184 (36.0) 185 (36.3)
Number of gout flares in the past 12 months, mean (S.D.) 5.5 (4.7) 6.0 (7.1) 5.8 (5.5)
Renal function at baseline, n (%), ml/min
eCrCl 590 180 (34.9) 200 (39.1) 203 (39.8)
eCrCl 60<90 229 (44.4) 208 (40.7) 213 (41.8)
eCrCl 30<60 101 (19.6) 101 (19.8) 92 (18.0)
eCrCl <30 4 (0.8) 1 (0.2) 0
sUA level at baseline, mean (S.D.), mg/dl 6.6 (1.50) 6.6 (1.5) 6.5 (1.45)
Comorbidities, n (%)
Hypertension 340 (65.9) 330 (64.6) 325 (63.7)
Hyperlipidaemia 221 (42.8) 230 (45.0) 241 (47.3)
Diabetes mellitus 80 (15.5) 96 (18.8) 78 (15.3)
Kidney stones 82 (15.9) 58 (11.4) 51 (10.0)
Myocardial infarction 19 (3.7) 26 (5.1) 22 (4.3)
eCrCl: estimated creatinine clearance; LESU: lesinurad; sUA: serum urate; XOI: xanthine oxidase inhibitor.
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The most common individual TEAEs were upper re-
spiratory tract infections and nasopharyngitis; EAIRs
were less in the core + extension studies than the core
studies (Table 2). The most common serious TEAEs were
acute myocardial infarction, coronary artery disease and
acute renal failure. EAIRs were low in the core studies and
did not increase in the core + extension studies.
Renal-related adverse event rates
The EAIRs for any renal-related TEAE, any renal-related
TEAE possibly related to randomized study medication
and any renal-related serious TEAE in the core studies
were similar with LESU200+XOI and XOI alone and were
higher with LESU400+XOI (Fig. 1). EAIRs for kidney stone
TEAEs and serious kidney stone TEAEs in the core studies
were less with LESU200+XOI than with XOI alone and
were greater with LESU400+XOI. Longer exposure in the
extension studies did not increase the EAIRs for any of
these TEAEs.
The most common renal-related TEAE was increased
blood creatinine, for which the rate was dose-ordered.
Others were increased blood urea nitrogen, renal failure
and renal impairment where the rates were low and gen-
erally similar across treatment groups (Table 3). Rates for
these TEAEs were not increased in the core + extension
studies. The most common MedDRA-defined serious
renal-related TEAEs were acute renal failure, renal failure,
chronic renal failure and renal impairment (Table 3). In the
core studies, these serious AEs only occurred in the XOI
alone (acute renal failure only) and the LESU400+XOI
groups, with EAIRs ranging from 0 to 0.5 events per 100
PY. In the core + extension studies, EAIRs for these
serious AEs were 40.2 except for acute renal failure in
the LESU400+XOI group (1.0).
EAIRs for sCr elevations 51.5 baseline in the core
studies were dose-ordered, being lowest with XOI alone
and highest with LESU400+XOI (Fig. 2A). EAIRs were also
dose-ordered in the core + extension studies, with the rate
the same in the LESU200+XOI group and lower in the
LESU400+XOI group than in the core studies. The per-
centage of events that resolved during the studies (sCr
41.2 baseline) ranged from 75% (9/12 events) in the
core XOI group to 92% (80/87 events) in the core
LESU400+XOI group and was 8990% in the core + ex-
tension groups (Fig. 2B). The percentage that resolved
without interruption of study medication was 6668% for
all LESU-treated groups and 75% for the core XOI group.
EAIRs for sCr elevations 52.0 baseline were lower, but
the pattern was similar to elevations 51.5 baseline
(Fig. 2C). The percentage of events that resolved ranged
from 80% (32/40 events) in the core LESU400+XOI group
to 92% (8/9 events) in the core LESU200+XOI group and
was 87% in both core + extension groups (Fig. 2D). The
percentage that resolved without interruption of study
medication ranged from 42% (13/31 events) in the core
+ extension 200CONT+XOI group to 67% (6/9 events) in
the core LESU200+XOI group. The percentage was 58%
(23/40 events) in the core LESU400+XOI group and 59%
(45/76) in the core + extension 400CONT+XOI group.
MACE rates/CV adverse events
In the core studies, there were four adjudicated MACEs
that occurred in 3/516 patients (0.6%) on XOI alone, four
events in 4/511 patients (0.8%) on LESU200+XOI, and
TABLE 2 Pooled analysis of exposure-adjusted TEAE incidence in core and core + extension studies
Adverse event category, n (rate)
Core studies Core + extension studies
XOI alone
LESU200
mg+XOI
LESU400
mg+XOI
LESU200
mg+XOI
LESU400
mg+XOI
(n= 516) (n= 511) (n= 510) (n= 666) (n= 666)
(PY = 408.5) (PY = 396.3) (PY = 390.5) (PY = 1251.5) (PY = 1236.5)
Any TEAE 363 (88.9) 386 (97.4) 407 (104.2) 546 (43.6) 568 (45.9)
Upper respiratory tract infection 44 (10.8) 46 (11.6) 57 (14.6) 85 (6.8) 96 (7.8)
Nasopharyngitis 43 (10.5) 45 (11.4) 47 (12.0) 83 (6.7) 83 (6.7)
Any TEAE with RCTC toxicity grade 3 or 4 48 (11.8) 52 (13.1) 67 (17.2) 112 (8.9) 134 (10.8)
Any TEAE possibly related to randomized
study medication
80 (19.6) 98 (24.7) 118 (30.2) 172 (13.7) 203 (16.4)
Any TEAE possibly related to XOI 52 (12.7) 49 (12.4) 66 (16.9) 84 (6.7) 111 (9.0)
Any TEAE possibly related to prophylaxis 52 (12.7) 56 (14.1) 61 (15.6) 78 (6.2) 82 (6.6)
Any serious TEAE 29 (7.1) 24 (6.1) 44 (11.3) 79 (6.3) 97 (7.8)
Acute myocardial infarction 0 1 (0.3) 4 (1.0) 3 (0.2) 5 (0.4)
Coronary artery disease 0 3 (1.8) 2 (0.5) 4 (0.3) 4 (0.3)
Acute renal failure 2 (0.5) 0 2 (0.5) 3 (0.2) 12 (1.0)
Any fatal TEAE 0 2 (0.5) 3 (0.8) 10 (0.8) 8 (0.6)
Any TEAE leading to discontinuation of LESU 28 (6.9) 32 (8.1) 48 (12.3) 84 (6.7) 107 (8.7)
Exposure-adjusted incidence rates are expressed as patients with events per 100 person-years. LESU200/400: lesinurad
200 mg/400; PY: person-years; RCTC: Rheumatology Common Toxicity Criteria; TEAE: treatment-emergent adverse event;
XOI: xanthine oxidase inhibitor.
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nine events in 8/510 patients (1.6%) on LESU400+XOI.
The higher incidence with LESU400+XOI was driven by
a higher incidence of nonfatal myocardial infarction (XOI,
1; LESU200+XOI, 2; LESU400+XOI, 7). In the core +
extension studies, there were 17 MACE in 16/666 patients
(2.4%) in the LESU200+XOI group and 17 events in 15/66
patients (2.3%) in the LESU400+XOI group. The higher
incidence of nonfatal myocardial infarction observed
FIG. 1 Exposure-adjusted rates of renal-related TEAEs
Pooled analysis of exposure-adjusted incidence rates of any renal-related TEAE (A), any renal-related TEAE leading to
LESU discontinuation (B), any renal-related serious TEAE (C), kidney stone TEAEs (D), and serious kidney stone TEAEs
(E) in core and core + extension studies. LESU200/400: lesinurad 200 mg/400 mg; PY: person-years; TEAEs: treatment-
emergent adverse events; XOI: xanthine oxidase inhibitor.
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with LESU400+XOI in the core studies was retained in the
core + extension studies (LESU200+XOI, 5; LESU400+
XOI, 9). Exposure-adjusted MACE rates in the core and
core + extension studies are shown in Fig. 3.
The most common individual cardiac TEAE was angina.
In the core studies, the EAIR was 0.5 patients with an
event per 100 PY with an XOI alone, 1.0 with
LESU200+XOI and 1.5 with LESU400+XOI, and was 0.5
and 0.6 with LESU200+XOI and LESU400+XOI, respect-
ively, in the core + extension studies. The most common
vascular TEAE was hypertension. The EAIRs in the core
studies were 6.1, 7.8 and 9.0, respectively, and 5.0 and
6.4 in the core + extension studies, respectively.
Discussion
In this integration of clinical trials, LESU at the sole
approved dose of 200 mg/day combined with an XOI
demonstrated a consistent safety profile in the core stu-
dies with TEAE rates that did not differ from XOI mono-
therapy. Rates with LESU400+XOI were higher than XOI
alone or LESU200+XOI. A similar pattern was observed in
the core studies for renal-related AEs, except for higher
rates of sCr elevations. Renal safety was of special inter-
est because many gout patients have significant comorbid
illnesses, including chronic kidney disease, diabetes,
hypertension and heart failure, and certain medications
used for these conditions that put them at increased risk
for adverse effects related to the kidney [2123]. That risk
might theoretically be increased in patients treated with
LESU because the drug is rapidly absorbed and rapidly
increases urinary uric acid excretion, although an exact
mechanism for the effects of LESU on the kidney is un-
known. However, the rates of renal-related TEAEs were
similar with XOI alone and LESU200+XOI, except for
higher rates of sCr elevations. Rates were higher with
LESU400+XOI. The rate of kidney stone TEAEs was actu-
ally less with LESU200+XOI than with XOI alone, while
rates were higher with LESU400+XOI. Serious kidney
stone TEAEs were rare in any treatment group.
Extended exposure to LESU did not lead to higher
EAIRs of TEAEs, renal-related TEAEs, or kidney stone
TEAEs in the core + extension studies than those
observed in the core studies. Overall, the renal safety pro-
file in the core + extension studies was consistent with
that observed in the core studies, and no new safety con-
cerns were identified in the extension studies.
The mechanism underlying the elevation of sCr levels is
not fully known, but it may be due to increased excretion
and microcrystallization of urinary uric acid in renal tu-
bules. The vast majority of sCr elevations in the core
and core + extension studies resolved, most often without
an interruption of study medication. When LESU was
interrupted, it was resumed when sCr was 40.1 mg/dl
greater than the baseline value. There was no apparent
association between the incidence of sCr elevations and
baseline renal function (eCrCl category 590, <90, 560,
545 and <45 ml/min), and therefore no evidence that pa-
tients with impaired renal function at baseline were at an
increased risk for sCr elevations. In fact, the incidence of
sCr elevations was lower in those with eCrCl <60 ml/min,
presumably because less was excreted in the urine. There
was also no apparent relationship between the incidence
of sCr elevations and either the presence/absence of
tophi at screening or gout flare prophylaxis medication
(NSAID/colchicine). An exploratory analysis was con-
ducted to identify potential predictors of sCr elevations
and to determine whether any subgroup of patients had
an increased risk for sCr elevations. 300 parameters
were evaluated: baseline laboratory values and vital
signs, all AEs, concomitant medications, questionnaire
scores, physical examination results, medical history,
TABLE 3 Exposure-adjusted incidence rates of renal-related adverse events
Core studies Core + extension studies
XOI alone
(n= 516)
(PY = 408.5)
LESU200+XOI
(n= 511)
(PY = 396.3)
LESU400+XOI
(n= 510)
(PY = 390.5)
LESU200+XOI
(n= 666)
(PY = 1251.0)
LESU400+XOI
(n= 666)
(PY = 1236.4)
Most common renal-related TEAEs, n (rate)
Increased blood creatinine 12 (2.9) 22 (5.6) 40 (10.2) 70 (5.6) 105 (8.5)
Increased blood urea 3 (0.7) 7 (1.8) 7 (1.8) 13 (1.0) 15 (1.2)
Renal failure 6 (1.5) 4 (1.0) 6 (1.5) 5 (0.4) 13 (1.1)
Renal impairment 0 1 (0.3) 5 (1.3) 6 (0.5) 11 (0.9)
Acute renal failure 2 (0.5) 0 4 (1.0) 4 (0.4) 17 (1.9)
Most common serious
renal-related TEAEs, n (%)
Acute renal failure 2 (0.5) 0 2 (0.5) 3 (0.2) 12 (1.0)
Renal failure 0 0 1 (0.3) 0 1 (0.1)
Chronic renal failure 0 0 1 (0.3) 0 1 (0.1)
Renal impairment 0 0 1 (0.3) 1 (0.1) 1 (0.1)
Exposure-adjusted incidence rates are expressed as patients with events per 100 person-years. LESU200/400: lesinurad 200
mg/400 mg; PY: patient years; sCr: serum creatinine; TEAEs: treatment-emergent adverse events; XOI: xanthine oxidase
inhibitor.
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ECG data and gout flare data. No strong predictors of sCr
elevations were identified. Baseline urinary uric acid, urin-
ary creatinine and sCr and parameters related to general
health (body mass index, smoking, physical functioning)
were associated with elevations; however, none of the
associations was strong enough to be of practical import-
ance in either predicting sCr elevations or in identifying a
subgroup of patients with increased risk.
CV safety was also of special interest because hyper-
uricaemia and gout are associated with increased CV
events and mortality. While the MACE rates in the core
studies appeared to be dose-ordered, assessment of
treatment-associated differences in risk is limited due to
the small number of MACE. Hence, a causal relationship
with LESU has not been determined.
The observed MACE rate for the total population of
LESU-treated patients was virtually identical to the rate
in a prospective study of 1732 patients with gout treated
with allopurinol for 6 months [7]. In that study, which
included the same entry criteria and prospective adjudi-
cation of potential CV events utilized in the LESU clinical
programme, the MACE rate was 1.42 events per 100 PY
(95% CI: 0.68, 2.62) (10 MACE events, 703.2 PY; 95% CI
based on Poisson distribution). In addition, the CV mor-
tality rate in the LESU treatment groups in the core studies
(0.48 CV deaths per 100 PY [95% CI: 0.18, 1.29]) was
lower than the unadjusted CV mortality rate among pa-
tients with gout from the National Health and Nutrition
Examination Survey (NHANES) (2.31 CV deaths per 100
PY) [24]. The rates are also broadly similar to other long-
term follow-up studies of patients with gout [25, 26].
Limitations to the studies include the inability to follow
all dropouts and patients after the study who had sCr
elevations. In order to capture the clinical diagnoses pro-
vided by investigators, a predefined list of MedDRA terms
that included such terms as renal failure, acute renal
FIG. 2 Exposure-adjusted rates of sCr elevations and resolution of sCR elevations
Exposure-adjusted rates of serum creatinine 1.5  baseline (A) and 2.0  baseline (C) and resolution of the elevations (B
& D, respectively) in the core and core + extension studies. LESU200/400: lesinurad 200 mg/400 mg; PY: person-years;
sCr: serum creatinine; XOI: xanthine oxidase inhibitor.
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failure and chronic renal failure was used without a distinct
definition for each term.
LESU, at the approved dose of 200 mg once daily com-
bined with an XOI, did not increase renal, CV or other AEs
compared with an XOI alone in the core studies, except
for a higher rate of sCr elevations. With extended expos-
ure in the extension studies, the renal safety profile was
consistent with that observed in the core studies, and no
new safety concerns were identified.
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